Paloma Partners’s Medifast MED Stock Holding History

Paloma Partners’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-16,870	Closed	-$368K	–	1477
2024 Q2	$368K	Buy	+16,870	New	+$450K	0.01%	857
2022 Q1	–	Sell	-3,939	Closed	-$825K	–	2062
2021 Q4	$825K	Buy	3,939 +1,157	+42%	+$239K	0.01%	813
2021 Q3	$536K	Buy	2,782 +1,055	+61%	+$259K	0.01%	524
2021 Q2	$489K	Sell	1,727 -3,160	-65%	-$856K	0.01%	1020
2021 Q1	$1.03M	Buy	+4,887	New	+$1.17M	0.02%	670
2020 Q4	–	Sell	-3,508	Closed	-$577K	–	1999
2020 Q3	$577K	Buy	+3,508	New	+$578K	0.01%	1068
2020 Q1	–	Sell	-5,200	Closed	-$570K	–	1734
2019 Q4	$570K	Buy	5,200 +3,091	+147%	+$299K	0.01%	1316
2019 Q3	$219K	Sell	2,109 -1,935	-48%	-$208K	﹤0.01%	1710
2019 Q2	$519K	Buy	+4,044	New	+$562K	0.01%	1013
2018 Q2	–	Sell	-2,708	Closed	-$252K	–	1986
2018 Q1	$252K	Buy	+2,708	New	+$202K	﹤0.01%	1699

Other funds holding MED

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paloma Partners's MED Position: Q3 2024 in Review

Paloma Partners sold out of Medifast (MED) in Q3 2024, closing a stake of 16,870 shares — an estimated $368K sold.

Paloma Partners first reported a position in MED in Q1 2018 and held it in 10 quarters. The position peaked at $1.03M in Q1 2021. 140 funds tracked by Wall St. Rank hold MED as of Q3 2024.

Paloma Partners reported no remaining Medifast position as of Q3 2024 after selling out during the quarter.
Paloma Partners sold 16,870 Medifast shares in Q3 2024, an estimated $368K.
Paloma Partners first reported a position in Medifast in Q1 2018 and held it in 10 quarters.
Paloma Partners's Medifast position peaked at $1.03M in Q1 2021.
140 funds tracked by Wall St. Rank held Medifast as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.